VTU Technology is now VALIDOGEN
Conferences & Exhibitions
Read our latest article "What about Pichia" reviewing recent advances in optimising Pichia
European Biopharmaceutical Review July 2017, ...
Launch of first joint product – VEGF 165 for cell culture applications
Biomay to apply VTU Pichia strains for the production of recombinant allergens
VTU Technology to offer unique combination of technologies for the high-level production of proteins with human-like glycosylation using Pichia ...
With more than 300 employees and 15 sites, VTU is now competing in the premier league of technology service providers.
VTU Technology and Minapharm Pharmaceuticals announced today, that they have entered into a licensing agreement to develop a therapeutic, recombinant ...
DNA2.0 and VTU to Develop an Optimized Gene Design for Pichia Pastoris
Almac and VTU Technology form collaboration to provide customers with high yielding, fast-track generation of site-specific modified products
VTU Technology, a leading contract research and development company providing services for the fast-track generation of high-performance industrial ...
Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive ...
Tablet Potrait-Mode gerade in Arbeit, bitte drehen Sie das Tablet in den Landscape-Mode.